- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01749046
Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures
May 10, 2017 updated by: Valexfarm
Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose of Remegal as Adjunctive Therapy in Patients With Partial Seizures
The purpose of this study is to determine weather Remegal in fixed dosage 1500 mg/daily is effictive and safe in patients with epilepsy with partial seizures
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Phase III
Study Type
Interventional
Enrollment (Actual)
224
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ekaterinburg, Russian Federation, 620036
- Sverdlovsk region neuropsychiatric clinic
-
Kemerovo, Russian Federation, 650036
- Region psychiatric clinic
-
Moscow, Russian Federation, 127083
- Moscow regional psychiatric hospital
-
Novosibirsk, Russian Federation, 630091
- State Medical University
-
Saint-Petersburg, Russian Federation, 193167
- State psychiatric hospital №6
-
Samara, Russian Federation, 443099
- State Medical University
-
Saransk, Russian Federation, 430030
- Republican psychiatric dispensary
-
Smolensk, Russian Federation, 214019
- State Medical Academy
-
Yaroslavl, Russian Federation, 150007
- Medical unit of disel equipment
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Man or woman, aged from 18 to 65
- Diagnosis of epilepsy with simple and/or complex partial seizures both with or without secondary generalization based on the ILAE classification
- Results of at least one prior electroencephalogram (EEG) and magnetic resonance imaging (MRI)/computerized tomography scan no more than 5 years should confirm the diagnostic of partial seizures
- If seizures are simple partial ones, only patients with motor signs must be enrolled
- The onset date of partial seizures according to patient's report must be at least 2 years
- The patient must report an average of at least 8 partial seizures per 56 days prior to the baseline visit
- The patient must not have seizure-free period longer than 21 days during the 8 weeks prior to the baseline visit (i.e between V1 and V2)
- Patients must have been treated with at least 2 different AEDs within the last 2 years prior to the screening visit
- The patient is capable and would like to respect all protocol requirements, include to be available for the doctor's calls and doctor's appointments at any time, follow through all protocol procedures
- The patient agrees to self - report each seizure he has experienced between 2 visits, accurately and thoroughly, in a diary he'll be provided with
Exclusion Criteria:
- Patients suffering from non-epileptic seizures
- Patients having seizures that can't be counted due to clustering.
- History of primary generalized seizures
- History of status epilepticus within 12 months prior to the screening visit
- The patient has received not permitted concomitant medications
- The patient has a progressive structural lesion in the CNS, or a progressive encephalopathy
- The patient is pregnant (or planning to become pregnant during the study) or is a lactating woman
- The patient has used Remegal previously or participated in a clinical study within 24 weeks prior to the screening visit
- The patient has experienced of any somatic disorders or psychiatric diseases and conditions which, in the opinion of the investigator, lead to health worsening or influence on the patient ability to participate in the actual clinical study
- Vulnerable patients and individuals of majority age who are subject to legal protection or unable to express their consent
- The patient has a history of chronic alcohol consumption or drug abuse within 2 years prior to the screening visit
- The patient has a known history of a severe anaphylactic reaction or severe changes in blood tests
- ALT, AST, alkaline phosphatise, total bilirubin or serum creatinine level ≥ 2 times the upper limit of normal ranges
- Clinically important abnormalities on physical examination, vital signs, ECG or laboratory test results per-formed/obtained at the screening visit that may interfere with patient's safety, compliance, or study evaluations, ac-cording to the Investigator's opinion
- The patient has a clinically significant disease, surgical condition or recent chronic consumption of non-AED medications (within 4 weeks prior to the screening visit) that might be reasonably expected to interfere with drug absorption, distribution, metabolism, excretion
- QTc interval on the ECG performed at the screening visit above 500 ms
- Diseases or concomitant medications that may prolong QTc interval
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Remegal 1500 mg for 12 weeks
Other Names:
|
Experimental: Remegal
Remegal 1500 mg
|
Remegal 1500 mg for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seizure Frequency Reduction
Time Frame: 12 weeks
|
The assessment of efficacy will be based on the reduction of total partial seizure frequency reported in the patient's diary during the Treatment phase.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Seizure's-Free Days
Time Frame: 12 weeks
|
Number seizure's-free days during the Maintenance phase
|
12 weeks
|
CGI
Time Frame: 12 weeks
|
Clinical Global Impression of change (CGI) at the end of Titration and Maintenance phases
|
12 weeks
|
PGI
Time Frame: 12 weeks
|
Patients' Global Impression of change (PGI) at the end of the Titration and Maintenance phases
|
12 weeks
|
QOLIE
Time Frame: 14 weeks
|
Assessment of Quality of Life Instrument in Epilepsy (QOLIE) at the Baseline Visit and at the end of Maintenance Phase
|
14 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (Actual)
October 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
December 11, 2012
First Submitted That Met QC Criteria
December 11, 2012
First Posted (Estimate)
December 13, 2012
Study Record Updates
Last Update Posted (Actual)
May 11, 2017
Last Update Submitted That Met QC Criteria
May 10, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-MPP02EPI
- 11-МРР02ЕРI (Other Identifier: Ministry of Health of Russian Federation)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on Remegal
-
ValexfarmCompletedSelf Efficacy | Drug Safety | Normal Drug ToleranceRussian Federation